Depomed (DEPO) has risen sharply, recording gains of 3.85% in the past 4 weeks. However, the stock has corrected -4.97% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.07% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 4.52% and the fifty day Moving Average is 0.37%. Depomed, Inc. has dropped 3.15% during the last three month period . Year-to-Date the stock performance stands at 8.66%.
Depomed (DEPO) : The most positive equity analysts on Depomed (DEPO) expects the shares to touch $36, whereas, the least positive believes that the stock will trade at $14 in the short term. The company is covered by 12 Wall Street Brokerage Firms. The average price target for shares are $23.75 with an expected fluctuation of $5.38 from the mean.
Depomed (NASDAQ:DEPO): On Fridays trading session , Opening price of the stock was $19.75 with an intraday high of $20.15. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $19.45. However, the stock managed to close at $19.7, a loss of 0.35% for the day. On the previous day, the stock had closed at $19.77. The total traded volume of the day was 879,397 shares.
Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.